Bliss GVS Pharma Limited (BLISSGVS.BO)
INR 120.15
(3.0%)
INR 120.15
(3.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 355.92 Million INR | -18.0% |
| 2022 | 434.07 Million INR | 62.49% |
| 2021 | 267.14 Million INR | -22.42% |
| 2020 | 344.33 Million INR | -14.37% |
| 2019 | 402.12 Million INR | 23.59% |
| 2018 | 325.37 Million INR | 450.04% |
| 2017 | 59.15 Million INR | -76.87% |
| 2016 | 255.8 Million INR | -43.99% |
| 2015 | 456.73 Million INR | -20.23% |
| 2014 | 572.58 Million INR | -34.63% |
| 2013 | 875.88 Million INR | -4.06% |
| 2012 | 912.98 Million INR | 142.63% |
| 2011 | 376.29 Million INR | 356.7% |
| 2010 | 82.39 Million INR | 7.82% |
| 2009 | 76.42 Million INR | 216.48% |
| 2008 | 24.14 Million INR | -30.92% |
| 2007 | 34.95 Million INR | -54.2% |
| 2006 | 76.31 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 284.96 Million INR | 0.0% |
| 2023 Q2 | 571.12 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 355.92 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 355.92 Million INR | -18.0% |
| 2022 Q2 | 376.86 Million INR | 0.0% |
| 2022 Q4 | 434.07 Million INR | 0.0% |
| 2022 FY | 434.07 Million INR | 62.49% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 330.67 Million INR | 0.0% |
| 2021 FY | 267.14 Million INR | -22.42% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 267.14 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 344.33 Million INR | -14.37% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 344.33 Million INR | 0.0% |
| 2020 Q2 | 487.11 Million INR | 0.0% |
| 2019 Q2 | 457.98 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 402.12 Million INR | 23.59% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 402.12 Million INR | 0.0% |
| 2018 Q2 | 130.5 Million INR | 0.0% |
| 2018 FY | 325.37 Million INR | 450.04% |
| 2018 Q4 | 325.37 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 59.15 Million INR | -76.87% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 200.49 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 59.15 Million INR | 0.0% |
| 2016 Q4 | 451.3 Million INR | 0.0% |
| 2016 FY | 255.8 Million INR | -43.99% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 293.72 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q4 | 456.73 Million INR | 0.0% |
| 2015 FY | 456.73 Million INR | -20.23% |
| 2014 FY | 572.58 Million INR | -34.63% |
| 2013 FY | 875.88 Million INR | -4.06% |
| 2012 FY | 912.98 Million INR | 142.63% |
| 2012 Q2 | 1.08 Billion INR | 0.0% |
| 2012 Q4 | 912.98 Million INR | 0.0% |
| 2011 FY | 376.29 Million INR | 356.7% |
| 2010 FY | 82.39 Million INR | 7.82% |
| 2009 FY | 76.42 Million INR | 216.48% |
| 2008 FY | 24.14 Million INR | -30.92% |
| 2007 FY | 34.95 Million INR | -54.2% |
| 2006 FY | 76.31 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 43.397% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 98.333% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -141.123% |
| Granules India Limited | 689.71 Million INR | 48.395% |
| Indoco Remedies Limited | 3.51 Billion INR | 89.881% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | -51.327% |
| Alkem Laboratories Limited | 400 Million INR | 11.02% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -9883.787% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -1178.639% |
| Bajaj HealthCare Limited | 650.34 Million INR | 45.272% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 94.058% |
| Eris Lifesciences Limited | 6.54 Billion INR | 94.562% |
| FDC Limited | 2.46 Million INR | -14333.171% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 76.536% |
| Gufic Biosciences Limited | 1.53 Billion INR | 76.883% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -218.852% |
| Ipca Laboratories Limited | 5.8 Billion INR | 93.868% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -370.983% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 80.604% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 95.863% |
| Lupin Limited | 1.55 Billion INR | 77.079% |
| Mankind Pharma Limited | 248.67 Million INR | -43.126% |
| Medicamen Biotech Limited | 12.55 Million INR | -2734.902% |
| Medico Remedies Limited | 8.67 Million INR | -4004.267% |
| Megasoft Limited | 1.35 Billion INR | 73.773% |
| NATCO Pharma Limited | 53 Million INR | -571.551% |
| Piramal Pharma Limited | 24.83 Billion INR | 98.567% |
| RPG Life Sciences Limited | -30.3 Million INR | 1274.66% |
| Sigachi Industries Limited | 265.79 Million INR | -33.907% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -2576.105% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -67.606% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 29297.867% |
| Unichem Laboratories Limited | 382.22 Million INR | 6.881% |
| Wanbury Limited | 820 Million INR | 56.595% |
| Windlas Biotech Limited | 20.18 Million INR | -1663.736% |
| ZIM Laboratories Limited | 356 Million INR | 0.024% |
| Zydus Lifesciences Limited | 251 Million INR | -41.802% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -233.886% |
| Divi's Laboratories Limited | 20 Million INR | -1679.61% |
| Hester Biosciences Limited | 1.81 Billion INR | 80.419% |
| Procter & Gamble Health Limited | 68.8 Million INR | -417.328% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -2448.124% |
| Bal Pharma Limited | 363.82 Million INR | 2.172% |
| Strides Pharma Science Limited | 6.71 Billion INR | 94.7% |
| Venus Remedies Limited | 386.8 Million INR | 7.983% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -88880.5% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 74.633% |
| Shilpa Medicare Limited | 5.6 Billion INR | 93.646% |
| Aarti Drugs Limited | 2.75 Billion INR | 87.073% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 96.474% |
| Valiant Laboratories Limited | 746.63 Million INR | 52.33% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -50.559% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 66.369% |
| Themis Medicare Limited | 267.74 Million INR | -32.936% |
| Hikal Limited | 4.22 Billion INR | 91.583% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 97.781% |
| Sequent Scientific Limited | 1.42 Billion INR | 75.061% |
| Novartis India Limited | 50.7 Million INR | -602.016% |
| Wockhardt Limited | 8.91 Billion INR | 96.005% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 98.876% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 20.766% |
| Morepen Laboratories Limited | 33.64 Million INR | -958.032% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -166.526% |